Status
Conditions
Treatments
About
The focus of the study is on patients Parkinson's disease showing as well behavioral disorders that can be described as pathological and are summarized under the term impulse control disorder (ICD). Changes in behavior and also pathological disorders are a common side effect of treatment for Parkinson's disease. The goal of this academic study is to compare the effect of surgical (deep brain stimulation, DBS) treatment combined with a coordinated and adapted best medical treatment (BMT) to be compared with the effect of optimized best medical treatment (BMT) alone. The stimulation arm (DBS+BMT) as well as the medication arm (BMT only) will be monitored according to clinical routine. Participants will have to agree to be randomly assigned to either deep brain stimulation in combination with the best medical treatment (DBS group) or the best medical treatment alone (BMT group). Participants will have to come regularly according to clinical routine to the clinic and complete various questionaires and scales for the study.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Age at the time of enrollment: ≤ 70 years
Diagnosis of PD according to MDS clinical diagnostic criteria
Onset of first PD motor symptoms ≥ 4 years
Moderate or severe impulse control disorder or related behavioral disorders according to Ardouin, with at least 1 score greater than or equal to 3 (or at least 2 scores greater than or equal to 2) on the Ardouin behaviour scale with the following items considered to reflect ICBDs or related behaviors: pathological gambling, hypersexuality, shopping, eating, hobbyism, punding and compulsive medication use
MDS-UPDRS III improvement of ≥ 30% in the standardized levodopa test or classical Parkinsonian tremor at rest
Adaptation of medical therapy has been attempted
MoCA ≥ 24 in the meds on condition
BDI-II score < 20 in the meds on condition, or Patients with moderately severe depression with a BDI-II between 20 and 28 points, strict consideration must be made with the involvement of a psychiatrist. Patients must be willing and able to comply this.
Patients able to understand the study requirements and the treatment procedures
Written informed consent before any study-specific tests or procedures are performed
Exclusion Criteria:
Surgical contraindications to undergo DBS operation
Ongoing severe depression (BDI-II > 28)
suicidal ideation (item 9 of BDI-II > 1)
Dementia (MoCA < 24) in the meds on condition
Any prior movement disorder treatments that involved intracranial surgery/ablation or intracranial device implantation
Any other active implanted device that is likely to interfere with the implantation or functioning of the DBS system
Simultaneous participation in another clinical trial targeting or potentially interfering with ICD
Any history of recurrent seizures or haemorrhagic stroke
Fertile women not using adequate contraceptive methods
Any terminal illness with significantly reduced life expectancy which exclude DBS implantation according to standard clinical care
A female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception
Any impairment that would limit subject's ability to participate in the study and perform study procedures
Have any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints
Primary purpose
Allocation
Interventional model
Masking
60 participants in 2 patient groups
Loading...
Central trial contact
Guenther Deuschl, Prof.; Steffen Paschen, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal